Replimune Group, Inc.
REPLReplimune Group, Inc. is a biotechnology company focused on developing proprietary immunotherapies for cancer treatment. Its cathepsin-based oncolytic immunotherapies aim to activate the immune system to recognize and destroy tumors, with a focus on combining these therapies with other cancer treatments to enhance efficacy.
Company News
The global oncolytic virotherapy market is projected to grow from USD 49.73 million in 2025 to USD 153.31 million by 2031, with a CAGR of 20.64%. Growth is driven by rising cancer incidence, advances in genetic engineering, and synergistic combination therapies with checkpoint inhibitors. However, host immune system challenges and premature viral...
Replimune presented biomarker data showing RP1 plus nivolumab can potentially reverse resistance mechanisms to PD-1 blockade in advanced melanoma, demonstrating a 33.6% response rate and 24.8-month median response duration.
Replimune Group's stock surged after the FDA accepted its resubmitted Biologics License Application for RP1, an investigational drug targeting advanced melanoma when combined with Bristol Myers Squibb's Opdivo.
Replimune Group resubmitted a Biologics License Application to the FDA for RP1, an oncolytic immunotherapy for advanced melanoma patients who progressed on anti-PD-1 therapy. The PDUFA date is set for April 10, 2026.
Replimune reported positive phase 2 clinical trial results for RP1, an oncolytic immunotherapy, when combined with nivolumab in treating acral melanoma. The treatment showed a 44% objective response rate and a favorable safety profile for patients who had progressed on previous therapies.
